Rein Therapeutics Postpones Annual Shareholder Meeting Due to Lack of Quorum

Rein Therapeutics to Reconvene Annual Meeting



Rein Therapeutics, a biopharmaceutical firm listed on NASDAQ under the ticker RNTX, has declared the adjournment of its annual meeting of stockholders. The meeting, scheduled for June 24, 2025, was unexpectedly postponed as a quorum was not achieved. This decision was made to afford more time for the company's stockholders to cast their votes concerning various proposals detailed in the definitive proxy statement submitted to the Securities and Exchange Commission (SEC).

The annual meeting has been rescheduled for July 23, 2025, beginning at 9:00 a.m. Eastern Time. Participants can join the meeting through the virtual platform at www.meetnow.global/M4RTYCN. Despite the adjournment, the record date for stockholders to participate remains unchanged, set as close of business on May 5, 2025.

This postponement highlights the importance of stockholder participation in corporate governance, particularly for a clinical-stage biopharmaceutical company like Rein, which is pioneering innovative therapies for conditions with substantial unmet medical needs, such as orphan pulmonary and fibrosis indications.

The company has reaffirmed that no modifications will be made to the proposals set to be voted on during the annual meeting. Stockholders who have not voted yet are highly encouraged to make their voices heard prior to the deadline, which is 11:59 p.m. Eastern Time on July 22, 2025.

In light of the upcoming meeting, Rein's board of directors is promoting a vote of

Topics Other)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.